Previous 10 | Next 10 |
Reliq Health Technologies Inc (RQHTF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 CMG Holdings Group Inc (CMGO) is expected to report for Q1 2024 Todos Me...
The AZEK Company Inc. Class A (AZEK) is expected to report $0.26 for Q4 2023 Jeronimo Martins - S.G.P.S., S.A. ADR (JRONY) is expected to report $0.68 for Q3 2023 Britvic ADR (BTVCY) is expected to report for Q4 2023 WVS Financial Corp. (WVFC) is expected to report for quarter end 202...
Mesoblast Limited (MESO) is expected to report $-0.13 for Q1 2024
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States ...
2023-11-22 13:48:53 ET An Australian %Biotech company stole the show on Wednesday after it was announced that Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreemen...
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approxim...
2023-11-21 08:38:21 ET Mountain Crest Acquisition ( MCAF ) +40% . Anghami ( ANGH ) +35% . Symbotic ( SYM ) +27% . SILO Pharma ( SILO ) +25% Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Tech...
2023-11-01 14:52:35 ET More on Mesoblast Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript Mesoblast plunges as William Blair downgrades on FDA rejection Mesoblast cell therapy for gr...
2023-11-01 14:22:06 ET Summary MESO has a diversified portfolio targeting inflammatory conditions, majorly led by products Remestemcel-L and Rexlemestrocel-L. The recent FDA rejection of Remestemcel-L poses a challenge, but Mesoblast remains optimistic about eventual approval. ...
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023. Mesoblast Chief Executive Silviu Itescu said: ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...